Talactoferrin alfa: Phase II started

Agennix began a double-blind, placebo-controlled, U.S. Phase II trial(LF-0801) to evaluate oral talactoferrin or placebo 3 times daily until discharge or up to 28 days in 190 patients with at least 1 ...